A phase I/II study of a recombinant chimeric protein composed of transforming growth factor (TGF)-a and a mutated pseudomonas exotoxin termed PE38 (TP-38) in pediatric patients with recurrent or progressive supratentorial high grade gliomas

Trial Profile

A phase I/II study of a recombinant chimeric protein composed of transforming growth factor (TGF)-a and a mutated pseudomonas exotoxin termed PE38 (TP-38) in pediatric patients with recurrent or progressive supratentorial high grade gliomas

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2009

At a glance

  • Drugs TP 38 (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Planned end date (1 Jun 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top